2016 Clinical Development Disease Protein Production 
Codon
MARCH 24, 2024
Once approved, patent-protected drugs are the highest-margin physical products on the planet—even with the high price of bioreactors. The real cost is clinical development. In 2012, an Israeli company called Protalix gained approval for their plant-based enzyme product for Gaucher’s disease.
The Pharma Data
JANUARY 24, 2021
A key advantage of Elasmogen’s VNAR platform is the ability to bind to their target at sites that are inaccessible to human antibodies translating, in many cases, to increased potency and specificity against the disease.
Expert insights. Personalized for you.
87 
Let's personalize your content